ERBB2 and cancer: In the ER+HER2– group, several factors negatively impacted BCSS, such as grade 3, stage II and III, lymph node involvement, higher Ki67 index, increased entropy of Ki67-positive cancer cell rates, and ID of CD8+ T-cell density.